Alpha 2.0
Login Register
» Authors » Tito R Mendoza

Tito R Mendoza

Explore the profile of Tito R Mendoza including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 157
Citations 5827
Followers 0
Related Specialties
Oncology
Psychiatry
Critical Care
Top 10 Co-Authors
Charles S Cleeland
Xin Shelley Wang
Qiuling Shi
Loretta A Williams
Ethan Basch
David I Rosenthal
Amylou C Dueck
Ibrahima Gning
G Brandon Gunn
Sandra A Mitchell
Published In
J Pain Symptom Manage
Cancer
Support Care Cancer
Qual Life Res
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
Lee M, Mitchell S, Basch E, Mazza G, Langlais B, Thanarajasingam G, et al.
Qual Life Res . 2024 Nov; 34(2):495-507. PMID: 39503942
Background: We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) items and their composite scores. Methods: We...
2.
Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a diverse cancer sample
Mead-Harvey C, Basch E, Rogak L, Langlais B, Thanarajasingam G, Ginos B, et al.
Clin Trials . 2024 Oct; :17407745241286065. PMID: 39440720
Background/aims: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed to capture symptomatic adverse events from the patient perspective. We aim to describe statistical...
3.
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma
Cleeland C, Keating K, Cuffel B, Elbi C, Siegel J, Gerlinger C, et al.
Sci Rep . 2024 Jun; 14(1):14839. PMID: 38937473
We developed a composite symptom score (CSS) representing disease-related symptom burden over time in patients with malignant pleural mesothelioma (MPM). Longitudinal data were collected from an open-label Phase IIB study...
4.
Should We Use COMM (Current Opioid Misuse Measure) to Screen for Opioid Abuse in Patients With Cancer Pain?
Moryl N, Mendoza T, Horn S, Eustaquio J, Cleeland C, Inturrisi C
J Natl Compr Canc Netw . 2023 Nov; 21(11):1132-1140.e3. PMID: 37935105
Background: Growing concerns about opioid use disorder (OUD) and the resulting decrease in opioid availability for patients with cancer pain highlight the need for reliable screening tools to identify the...
5.
Pilot study of a Spanish language measure of financial toxicity in underserved Hispanic cancer patients with low English proficiency
Shi J, McGinnis G, Peterson S, Taku N, Chen Y, Yu R, et al.
Front Psychol . 2023 Jul; 14:1188783. PMID: 37492449
Background: Financial toxicity (FT) reflects multi-dimensional personal economic hardships borne by cancer patients. It is unknown whether measures of FT-to date derived largely from English-speakers-adequately capture economic experiences and financial...
6.
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
Williams L, Whisenant M, Mendoza T, Peek A, Malveaux D, Griffin D, et al.
J Patient Rep Outcomes . 2023 May; 7(1):48. PMID: 37237077
Background: Symptom expression in SARS-CoV-2 infection (COVID-19) may affect patients already symptomatic with cancer. Patient-reported outcomes (PROs) can describe symptom burden during the acute and postacute stages of COVID-19 and...
7.
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
Altan M, Soto F, Zhong L, Akhmedzhanov F, Wilson N, Zarifa A, et al.
Oncologist . 2023 May; 28(11):e1065-e1074. PMID: 37156009
Introduction: Immune checkpoint inhibitor (ICI) pneumonitis causes substantial morbidity and mortality. Estimates of real-world incidence and reported risk factors vary substantially. Methods: We conducted a retrospective review of 419 patients...
8.
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Jenkins S, Zhang W, Steinberg S, Nousome D, Houston N, Wu X, et al.
Clin Cancer Res . 2023 Jan; 29(8):1450-1459. PMID: 36705597
Purpose: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention...
9.
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study
Vera E, Christ A, Grajkowska E, Briceno N, Choi A, Crandon S, et al.
EClinicalMedicine . 2022 Nov; 55:101718. PMID: 36386035
Background: Recognising the importance of clinical outcomes assessments (COAs), the Response Assessment in Neuro-Oncology-Patient Reported Outcome (RANO-PRO) Working Group recommended inclusion of core symptoms and functions in clinical care or...
10.
Short-form adaptive measure of financial toxicity from the Economic Strain and Resilience in Cancer (ENRICh) study: Derivation using modern psychometric techniques
Xu C, Smith G, Chen Y, Checka C, Giordano S, Kaiser K, et al.
PLoS One . 2022 Aug; 17(8):e0272804. PMID: 36006909
Objectives: This study sought to evaluate advanced psychometric properties of the 15-item Economic Strain and Resilience in Cancer (ENRICh) measure of financial toxicity for cancer patients. Methods: We surveyed 515...